Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J DUDA

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1356436406
CMS profile
151655
Location
SPRINGFIELD, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$93,909.12

141 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $86,917.32 122
Amgen Inc. $6,801.29 9
Novo Nordisk Inc $57.55 2
Mallinckrodt Hospital Products Inc. $37.49 2
UCB, Inc. $33.38 2
AbbVie Inc. $29.52 2
Radius Health, Inc. $19.79 1
Janssen Biotech, Inc. $12.78 1

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J DUDA

NPI 1356436406 · CMS profile ID 151655

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

SPRINGFIELD, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J DUDA, NPI 1356436406, CMS profile ID 151655. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RALPH J DUDA, NPI 1356436406, CMS profile ID 151655. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RALPH J DUDA, NPI 1356436406, CMS profile ID 151655, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–141 of 141 matching records. This page contains 41 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1356436406?year=2023&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

141 matching records · $93,909.12 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 141 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–141 of 141.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $1,575.0004/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031956693 CMS
Lilly USA, LLC $1,800.0004/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031996623 CMS
Lilly USA, LLC $11.4904/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032051973 CMS
Lilly USA, LLC $1,125.0004/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031956689 CMS
Lilly USA, LLC $1,800.0004/12/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032051937 CMS
Mallinckrodt Hospital Products Inc. $21.6504/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042825713 CMS
Lilly USA, LLC $21.4404/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032051961 CMS
Lilly USA, LLC $1,800.0004/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078093 CMS
Lilly USA, LLC $1,125.0004/04/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032124731 CMS
Lilly USA, LLC $1,125.0003/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031996621 CMS
Lilly USA, LLC $1,800.0003/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078097 CMS
Lilly USA, LLC $17.7703/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031956761 CMS
Lilly USA, LLC $17.6503/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032007145 CMS
UCB, Inc. $14.4003/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021991613 CMS
Lilly USA, LLC $1,800.0003/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032007135 CMS
Lilly USA, LLC $675.0003/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032101317 CMS
Amgen Inc. $625.5003/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061168794 CMS
Lilly USA, LLC $12.2203/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032007139 CMS
Lilly USA, LLC $28.8203/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031956683 CMS
Lilly USA, LLC $32.0003/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032101313 CMS
Janssen Biotech, Inc. $12.7803/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988225249 CMS
Lilly USA, LLC $3,600.0003/03/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032124727 CMS
Lilly USA, LLC $6.2502/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032124721 CMS
Lilly USA, LLC $3.9502/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031996651 CMS
Lilly USA, LLC $35.0002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031996655 CMS
Lilly USA, LLC $45.0002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031996659 CMS
Lilly USA, LLC $36.5402/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032007169 CMS
Lilly USA, LLC $25.0002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032007173 CMS
Lilly USA, LLC $232.0002/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032022763 CMS
Lilly USA, LLC $17.5502/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032022769 CMS
Lilly USA, LLC $59.8702/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032022773 CMS
Lilly USA, LLC $220.0402/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032051932 CMS
Lilly USA, LLC $10.8002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032051983 CMS
Lilly USA, LLC $136.7502/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078127 CMS
Lilly USA, LLC $25.0002/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078131 CMS
Lilly USA, LLC $202.5802/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032124717 CMS
Lilly USA, LLC $9.4502/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032124753 CMS
Lilly USA, LLC $80.0002/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032101309 CMS
Lilly USA, LLC $108.7502/16/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031956681 CMS
UCB, Inc. $18.9802/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021991617 CMS
Lilly USA, LLC $61.2502/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032078089 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $166,521.37 241
PY2020 $89,520.14 124
PY2021 $42,352.07 63
PY2022 $91,556.46 131
PY2023 $93,909.12 141
PY2024 $83,108.52 121
PY2025 $77,300.35 131

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,357,953.33 228
PY2024 Principal investigator $179,334.40 7
PY2023 Principal investigator $463,266.44 7
PY2022 Recipient $44,029.00 3
PY2022 Principal investigator $400,653.00 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

228 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202533101
Principal investigator 1 ABBVIE INC. $189.00 12/26/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202532102
Principal investigator 1 PFIZER INC. $1,582.00 12/19/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228744304
Principal investigator 1 PFIZER INC. $12,541.11 12/17/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228733767
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,826.00 12/15/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812512
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,000.00 12/09/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812508
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $350.00 12/09/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812510
Principal investigator 1 ABBVIE INC. $420.00 12/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527876
Principal investigator 1 ABBVIE INC. $4,752.00 12/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527878
Principal investigator 1 ABBVIE INC. $231.00 12/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527880
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 12/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724251
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724253
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724255
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724257
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724259
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 12/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,678.50 11/25/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264511
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,722.00 11/20/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263655
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.80 11/20/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263657
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 11/20/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263659
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/20/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263661
Principal investigator 1 Eli Lilly and Company $1,020.92 11/19/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY4065967 FOR THE TREATMENT OF DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187878231
Principal investigator 1 PFIZER INC. $6,723.65 11/14/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228738368
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $9,055.00 11/13/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812506
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,853.20 11/13/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260693
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.00 11/07/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220807549
Principal investigator 1 PFIZER INC. $4,353.81 11/07/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228739316
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $506.10 11/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258961
Principal investigator 1 ABBVIE INC. $4,960.00 11/05/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522121
Principal investigator 1 ABBVIE INC. $63.00 11/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202520501
Principal investigator 1 ABBVIE INC. $413.00 11/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202520503
Principal investigator 1 PFIZER INC. $8,400.70 11/04/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228738536
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 11/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724239
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724241
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724243
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724245
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724247
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 11/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724249
Principal investigator 1 PFIZER INC. $3,483.20 11/01/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228738622
Principal investigator 1 AstraZeneca Pharmaceuticals LP $39,198.85 10/31/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease (ASCVD) or at High Risk for a First ASCVD Event No dispute reported 06/30/2026 1185553918
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,919.40 10/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253702
Principal investigator 1 Eli Lilly and Company $605.01 10/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187879517
Principal investigator 1 Boehringer Ingelheim International GmbH $23.32 10/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724263
Principal investigator 1 Boehringer Ingelheim International GmbH $179.82 10/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724265
Principal investigator 1 Boehringer Ingelheim International GmbH $365.00 10/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724267
Principal investigator 1 Boehringer Ingelheim International GmbH $10.44 10/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724269
Principal investigator 1 Boehringer Ingelheim International GmbH $11.04 10/27/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724271
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,722.00 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252612
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,918.80 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252614
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 10/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184252616
Principal investigator 1 PFIZER INC. $8,081.50 10/21/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228730734
Principal investigator 1 ABBVIE INC. $619.19 10/16/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202517335
Principal investigator 1 ABBVIE INC. $3,168.00 10/09/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202516365
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,386.00 10/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812482
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 10/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812484
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,155.00 10/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812486
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 10/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812488
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,309.00 10/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812490
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 10/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812492
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 10/03/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812494
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 10/03/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812496
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,410.00 10/03/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812498
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $231.00 10/03/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812500
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $154.00 10/03/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812502
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $385.00 10/03/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812504
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 10/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724227
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724229
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724231
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724233
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724235
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 10/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724237
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $580.00 10/01/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812480
Principal investigator 1 ABBVIE INC. $350.00 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202511904
Principal investigator 1 ABBVIE INC. $126.00 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202511908
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,422.54 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241608
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241634
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,120.00 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241636
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.80 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241638
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.60 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241640
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $861.00 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241642
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241644
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.80 09/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184241646
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,215.00 09/18/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812478
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 09/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236572
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,200.00 09/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236574
Principal investigator 1 ABBVIE INC. $91.40 09/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509436
Principal investigator 1 ABBVIE INC. $518.00 09/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509438
Principal investigator 1 ABBVIE INC. $413.00 09/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509440
Principal investigator 1 ABBVIE INC. $126.00 09/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509442
Principal investigator 1 ABBVIE INC. $55.00 09/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509566
Principal investigator 1 ABBVIE INC. $8,968.00 09/04/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509568
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724193
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724195
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724197
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724199
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 09/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724201
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 09/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724217
Principal investigator 1 Boehringer Ingelheim International GmbH $30.79 09/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724225
Principal investigator 1 PFIZER INC. $8,333.50 08/22/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228720369
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,032.82 08/21/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229741
Principal investigator 1 Eli Lilly and Company $6,521.15 08/18/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187880149
Principal investigator 1 PFIZER INC. $2,181.57 08/15/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228786633
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,835.14 08/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226133
Principal investigator 1 ABBVIE INC. $9,724.00 08/06/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202502981
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $30,987.00 08/06/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812476
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,520.00 08/05/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812474
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724181
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724183
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724185
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724187
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724189
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 08/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724191
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 08/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724215
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 07/30/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812464
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 07/30/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812466
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 07/30/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812468
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 07/30/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812470
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,540.00 07/30/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812472
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 07/28/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724219
Principal investigator 1 Boehringer Ingelheim International GmbH $110.55 07/28/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724221
Principal investigator 1 Boehringer Ingelheim International GmbH $8.70 07/28/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724223
Principal investigator 1 ABBVIE INC. $1,134.61 07/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202499668
Principal investigator 1 ABBVIE INC. $500.00 07/22/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202499122
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,079.42 07/22/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184217761
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,950.00 07/19/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812462
Principal investigator 1 PFIZER INC. $13,876.60 07/18/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228774182
Principal investigator 1 ABBVIE INC. $63.00 07/17/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202498760
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $435.00 07/16/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812448
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $231.00 07/16/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812450
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $750.00 07/16/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812452
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $290.00 07/16/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812454
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $231.00 07/16/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812456
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $262.00 07/16/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812458
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,070.00 07/16/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812460
Principal investigator 1 ABBVIE INC. $63.00 07/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202498296
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,739.22 07/10/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214364
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $294.00 07/09/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812444
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,520.00 07/09/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812446
Principal investigator 1 ABBVIE INC. $3,168.00 07/02/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496439
Principal investigator 1 PFIZER INC. $5,000.00 07/02/2025 Non-covered Recipient Entity
Clinvest Headlands LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228763355
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724203
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724205
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724207
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724209
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 07/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724211
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 07/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724213
Principal investigator 1 Eli Lilly and Company $156,558.64 07/01/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY EVALUATING THE EFFICACY AND LONG-TERM SAFETY OF TIRZEPATIDE ONCE WEEKLY COMPARED TO PLACEBO IN ADULTS WITH TYPE 1 DIABETES AND OBESITY OR OVERWEIGHT (SURPASS-T1D-2) No dispute reported 06/30/2026 1187880145
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $36,792.00 06/26/2025 Non-covered Recipient Entity
Clinvest Headlands, LLC
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220812442
Principal investigator 1 ABBVIE INC. $63.00 06/25/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492835
Principal investigator 1 Boehringer Ingelheim International GmbH $81.62 06/24/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724179
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $755.72 06/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210642
Principal investigator 1 ABBVIE INC. $189.00 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492103
Principal investigator 1 ABBVIE INC. $1,680.00 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492105
Principal investigator 1 ABBVIE INC. $1,200.00 06/18/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492117
Principal investigator 1 ABBVIE INC. $210.00 06/17/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202491717
Principal investigator 1 Eli Lilly and Company $4,674.00 06/16/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 2 DIABETES CURRENTLY TREATED WITH BASAL INSULIN (QWINT-3) No dispute reported 06/30/2026 1187878229
Principal investigator 1 ABBVIE INC. $126.00 06/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202491049
Principal investigator 1 ABBVIE INC. $231.00 06/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202491089
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,114.42 06/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206241
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,722.00 06/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206243
Principal investigator 1 ABBVIE INC. $7,384.00 06/11/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202490837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,114.42 06/05/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204175
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724163
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724165
Principal investigator 1 Boehringer Ingelheim International GmbH $47.50 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724167
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724169
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724171
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724173
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724175
Principal investigator 1 Boehringer Ingelheim International GmbH $39.00 06/01/2025 Non-covered Recipient Entity
Clinvest Research
A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD No dispute reported 06/30/2026 1220724177
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,881.62 05/28/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198897
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $755.72 05/22/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184197655
Principal investigator 1 ABBVIE INC. $4,500.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202485211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,037.64 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194661
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $499.80 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194667
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.80 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194687
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 05/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194703
Principal investigator 1 ABBVIE INC. $189.00 05/14/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202484805
Principal investigator 1 Eli Lilly and Company $6,665.85 05/12/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187877937
Principal investigator 1 Eli Lilly and Company $7,544.00 05/12/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, MULTICENTER, RANDOMIZED, PARALLEL-DESIGN, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED WITH INSULIN DEGLUDEC IN PARTICIPANTS WITH TYPE 1 DIABETES TREATED WITH MULTIPLE DAILY INJECTION THERAPY No dispute reported 06/30/2026 1187878051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $755.72 05/08/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193759
Principal investigator 1 ABBVIE INC. $8,884.00 05/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482467
Principal investigator 1 ABBVIE INC. $126.00 04/30/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202480567
Principal investigator 1 ABBVIE INC. $63.00 04/30/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202480637
Principal investigator 1 Eli Lilly and Company $270.00 04/30/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187877189
Principal investigator 1 ABBVIE INC. $224.00 04/29/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202479855
Principal investigator 1 ABBVIE INC. $756.00 04/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202479095
Principal investigator 1 ABBVIE INC. $252.00 04/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202479099
Principal investigator 1 ABBVIE INC. $504.00 04/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202479103
Principal investigator 1 ABBVIE INC. $252.00 04/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202479370
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.60 04/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189105
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $58.80 04/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189107
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.60 04/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189109
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $117.60 04/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189111
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,860.00 04/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189113
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $166.60 04/23/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189115
Principal investigator 1 Eli Lilly and Company $248.77 04/21/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, PARALLEL-DESIGN, OPEN-LABEL, RANDOMIZED CONTROL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3209590 AS A WEEKLY BASAL INSULIN COMPARED TO INSULIN DEGLUDEC IN INSULIN NAIVE ADULTS WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187877585
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,367.44 04/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183434
Principal investigator 1 Eli Lilly and Company $1,182.00 04/08/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187878223
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,628.22 04/08/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182060
Principal investigator 1 ABBVIE INC. $5,704.00 04/03/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202474149
Principal investigator 1 Eli Lilly and Company $84,972.00 04/01/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187879275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,739.22 04/01/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180830
Principal investigator 1 Eli Lilly and Company $132,556.89 03/24/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RETATRUTIDE ONCE WEEKLY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND CHRONIC LOW BACK PAIN (TRIUMPH-7) No dispute reported 06/30/2026 1187877579
Principal investigator 1 Eli Lilly and Company $1,084.96 03/10/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882258
Principal investigator 1 ABBVIE INC. $7,652.00 03/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202460110
Principal investigator 1 Eli Lilly and Company $225.00 03/06/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187879273
Principal investigator 1 Eli Lilly and Company $4.54 03/03/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187879515
Principal investigator 1 Eli Lilly and Company $870.91 02/25/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187877583
Principal investigator 1 Eli Lilly and Company $32,393.00 02/18/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PARALLEL-GROUP, TWO-ARM, PHASE 4 STUDY TO EVALUATE THE LONG-TERM EFFICACY AND SAFETY OF TIRZEPATIDE COMPARED WITH INTENSIFIED CONVENTIONAL CARE IN ADULTS WHEN INITIATING TREATMENT EARLY IN THE COURSE OF TYPE 2 DIABETES No dispute reported 06/30/2026 1187878295
Principal investigator 1 ABBVIE INC. $4,120.00 02/06/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202448023
Principal investigator 1 Eli Lilly Export S.A. Puerto Rico Branch $506.00 01/31/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) No dispute reported 06/30/2026 1187880097
Principal investigator 1 Eli Lilly and Company $572.24 01/31/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187879521
Principal investigator 1 Eli Lilly and Company $4,386.15 01/31/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187882256
Principal investigator 1 Eli Lilly and Company $52.99 01/27/2025 Non-covered Recipient Entity
SCOTT HEALTH SERVICES LLC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187889398
Principal investigator 1 Eli Lilly and Company $3,203.18 01/22/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187879525
Principal investigator 1 Eli Lilly and Company $36,949.16 01/21/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A STUDY OF ORFORGLIPRON (LY3502970) IN PARTICIPANTS WITH TYPE 2 DIABETES AND INADEQUATE GLYCEMIC CONTROL WITH INSULIN GLARGINE, WITH OR WITHOUT METFORMIN AND/?OR SGLT-2 INHIBITOR (ACHIEVE-5) No dispute reported 06/30/2026 1187876587
Principal investigator 1 ABBVIE INC. $9,999.96 01/15/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202438685
Principal investigator 1 Eli Lilly and Company $19,015.00 01/13/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 3, 12 MONTH, OPEN LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE PIONEER PEDS2 No dispute reported 06/30/2026 1187876585
Principal investigator 1 Eli Lilly and Company $115,539.00 01/13/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3549492 ONCE DAILY COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187877935
Principal investigator 1 Eli Lilly and Company $44,324.52 01/13/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A STUDY OF DAILY ORAL ORFORGLIPRON (LY3502970) COMPARED WITH INSULIN GLARGINE IN PARTICIPANTS WITH TYPE 2 DIABETES AND OBESITY OR OVERWEIGHT AT INCREASED CARDIOVASCULAR RISK (ACHIEVE-4) No dispute reported 06/30/2026 1187879511
Principal investigator 1 Eli Lilly and Company $1,415.72 01/09/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
RANDOMIZED, PLACEBO CONTROLLED, PHASE 2 CLINICAL TRIAL TO EVALUATE LY3556050 FOR THE TREATMENT OF OSTEOARTHRITIS PAIN No dispute reported 06/30/2026 1187876589
Principal investigator 1 Eli Lilly and Company $8,834.99 01/09/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 2, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE WEIGHT MANAGEMENT WITH LY3841136 AND TIRZEPATIDE, ALONE OR IN COMBINATION, IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH TYPE 2 DIABETES No dispute reported 06/30/2026 1187878227
Principal investigator 1 Eli Lilly and Company $131,763.85 01/07/2025 Non-covered Recipient Entity
CLINVEST RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY No dispute reported 06/30/2026 1187878297
Principal investigator 1 Eli Lilly and Company $113,349.00 01/07/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR CHRONIC WEIGHT MANAGEMENT IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT No dispute reported 06/30/2026 1187879271
Principal investigator 1 ABBVIE INC. $3,168.00 01/02/2025 Non-covered Recipient Entity
CLINVEST HEADLANDS LLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202434481